ArticleMayo Clinic proceedings2020
Patterns of Cystatin C Uptake and Use Across and Within Hospitals.
Article in Mayo Clinic proceedings, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Toward the Future: A Race-Agnostic, Bayesian Approach to Defining Glomerular Filtration for Personalized Drug Dosing.Clinical pharmacology and therapeutics · 2026Review
- Outcomes and Risk Factors of Widened Difference in Estimated Glomerular Filtration Rate Based on Creatinine or Cystatin C: Adjust Model Development With More Than 300,000 UK Biobank Participants.Kidney medicine · 2026Article
- Nephrocast-V: A Deep Learning Model for the Prediction of Vancomycin Trough Concentration Using Electronic Health Record Data.Pharmacotherapy · 2026Article
- Cystatin C-Guided Dosing Nomogram Improves Target Attainment for Cefepime in the Critically Ill.Critical care medicine · 2025Article
- Establishing discordance rate of estimated glomerular filtration rate between serum creatinine-based calculations and cystatin-C-based calculations in critically ill patients.Pharmacotherapy · 2025Observational
- Challenges in renally eliminated medication use: Evaluating cystatin C and serum creatinine eGFR discordance.Pharmacotherapy · 2024Article
- Development and validation of a deep learning algorithm for the prediction of serum creatinine in critically ill patients.JAMIA open · 2024Article
- Drug stewardship in chronic kidney disease to achieve effective and safe medication use.Nature reviews. Nephrology · 2024Review
- Estimated GFR With Cystatin C and Creatinine in Clinical Practice: A Retrospective Cohort Study.Kidney medicine · 2023Article
- Prospective evaluation of high-dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney function.Clinical and translational science · 2022Observational
- Prediction of Vancomycin Levels Using Cystatin C in Overweight and Obese Patients: a Retrospective Cohort Study of Hospitalized Patients.Antimicrobial agents and chemotherapy · 2020Observational
- Clinician perspectives on inpatient cystatin C utilization: A qualitative case study at Mayo Clinic.PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo characterize the use of cystatin C (cysC) across and within hospitals. PATIENTS AND
methodsThis 2-part study first evaluated access to cysC testing across 129 hospitals in the state of Minnesota, using a telephone-based survey. Second, granular data from a single center (Mayo Clinic) with on-site, rapid-turnaround testing (<1 day) and automated estimated glomerular filtration rate (eGFR) reporting was used to describe temporal patterns. The characteristics of hospitals that offered cysC testing and of patients who underwent rapid cysC testing at Mayo Clinic between January 1, 2011, and March 31, 2018, were described. Poisson regression analyzed temporal trends in cysC testing.
resultsOf the 114 hospitals (88%) that responded to the statewide survey, cysC was available in 91 (80%), but only 3 of 91 (3%) reported a turnaround time of <1 day. At Mayo Clinic, cysC use increased from 0.74 tests per 1000 patient-days in 2011 to 14 tests per 1000 patient-days in 2018 (P=.004). Of the 3774 patients with cysC tests, the mean first available eGFR was 46 mL/min per 1.73 m
conclusionIn the hospital, rapid-turnaround cysC testing is necessary for practical use but was not widely available in Minnesota. When available, a marked increase in cysC testing was observed over the study timeframe. Additional research is needed to determine optimal strategies for implementation of cysC within hospitals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.